Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.

Current opinion in oncology

Volumn 24 Suppl 2, Issue , 2012, Pages

  Mariz, José Mário ^a   Esteves, Graça Vasconcelos ^b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DRUG DERIVATIVE; LENALIDOMIDE; THALIDOMIDE;

HUMAN; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; PRACTICE GUIDELINES AS TOPIC; THALIDOMIDE;

EID: 84873025221     PISSN: None     EISSN: 1531703X     Source Type: Journal    
DOI: None     Document Type: Review

References (0)